Sagimet (SGMT) Director Kemble George Sells 350,987 Shares

What Happened Kemble George, a director of Sagimet Biosciences (SGMT), exercised vested stock options to acquire a total of 350,987 shares and then sold those shares in the open market on August 14, 2026. He exercised 326,618 options at $6.36 each (cost $2,077,290) and 24,369 options at $6.36 each (cost $154,987), then sold 350,987 shares at a weighted-average price of $10.23 for proceeds of $3,591,580. The filing also reports the related derivative conversion entries (exercise of the options).

Key Details

• Transaction date: August 14, 2026; Form 4 filed Aug 17, 2026 (within the normal Form 4 filing window).
• Options exercised (code M): 326,618 @ $6.36 ($2,077,290) and 24,369 @ $6.36 ($154,987). Both options are reported as fully vested.
• Open-market sale (code S): 350,987 shares, weighted-average price $10.23, total proceeds $3,591,580. Sale prices ranged $9.95–$10.57 (filing footnote).
• Trades were effected pursuant to a Rule 10b5-1 trading plan adopted Aug 21, 2025 (filing footnote).
• Shares owned after the transactions are not specified in the provided filing excerpt.

Context

• Transaction codes: M = exercise/conversion of a derivative (options); S = sale. The filing shows the options were exercised (payment of the $6.36 strikes) and the resulting shares were sold in the open market under a pre‑arranged 10b5‑1 plan.
• This is a purchase (exercise) followed by a sale; purchases can be interpreted as an insider acquiring shares, but the subsequent sale under a 10b5‑1 plan indicates the disposition was pre‑planned.
• The filing is factual and timely; it does not state motivations or insider views.